Argentina celebrates a historic achievement in the field of public health: the National Administration of Medicines, Food and Medical Technology (ANMAT) has given the green light to the marketing and distribution of a national single-dose dengue vaccine. This milestone, developed entirely by researchers from the CONICET and the National University of La Plata (UNLP)positions our country at the global forefront in the fight against one of the most challenging diseases in the region.
The news, which resonates with particular force in a global context of growing concern about dengue, represents a transcendental step for the health of millions of people and a source of pride for Argentine science.
A Years of Research and Development Effort
The project, which has required years of research, investment and dedication, was led by a multidisciplinary team of virologists, immunologists and biotechnologists. The key to success lies in its innovative formulation, which allows a robust and long-lasting immune response with a single applicationdrastically simplifying vaccination schedules and facilitating their large-scale implementation.
«We are facing a paradigm shift in dengue prevention,» said Dr. Laura Giménez, head of the research team, in exclusive dialogue with Vive. «Single-dose not only simplifies logistics, but also guarantees greater adherence to vaccination, which is essential to achieve herd immunity and protect our communities.»
Regional Impact and Global Projection
The approval of this national vaccine has implications that transcend Argentine borders. With dengue being an epidemic that affects much of Latin America, the single-dose solution developed in the country is presented as a concrete hope for the entire region.
Sources from the National Ministry of Health announced that conversations have already begun with international health organizations and neighboring countries to explore cooperation mechanisms and guarantee that this innovative vaccine reaches as many people as possible at risk.
This achievement reinforces the value of investment in science and technology in Argentina and demonstrates the capacity of its institutions to generate solutions with global impact. With a dengue season that represents a greater challenge each year, the new national single-dose vaccine emerges as a fundamental tool to protect the population and transform the future of public health.
